CN102198125B - 咖啡酸苯乙酯类衍生物在制备抗肿瘤血管形成的药物中的用途 - Google Patents
咖啡酸苯乙酯类衍生物在制备抗肿瘤血管形成的药物中的用途 Download PDFInfo
- Publication number
- CN102198125B CN102198125B CN2011100721406A CN201110072140A CN102198125B CN 102198125 B CN102198125 B CN 102198125B CN 2011100721406 A CN2011100721406 A CN 2011100721406A CN 201110072140 A CN201110072140 A CN 201110072140A CN 102198125 B CN102198125 B CN 102198125B
- Authority
- CN
- China
- Prior art keywords
- tumor
- group
- medicine
- blood vessel
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 66
- 239000003814 drug Substances 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 title abstract description 12
- 230000033115 angiogenesis Effects 0.000 title abstract description 6
- 229940079593 drug Drugs 0.000 title abstract description 6
- SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical class C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 230000002792 vascular Effects 0.000 claims description 16
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 7
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 235000018259 Solanum vestissimum Nutrition 0.000 claims description 3
- 240000002825 Solanum vestissimum Species 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 3
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 abstract description 23
- 125000003118 aryl group Chemical group 0.000 abstract description 7
- 125000002947 alkylene group Chemical group 0.000 abstract description 4
- 125000001424 substituent group Chemical group 0.000 abstract description 4
- 229910052736 halogen Inorganic materials 0.000 abstract description 3
- 150000002367 halogens Chemical class 0.000 abstract description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract description 2
- 239000001257 hydrogen Substances 0.000 abstract description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract description 2
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 239000001301 oxygen Substances 0.000 abstract description 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract description 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000732 arylene group Chemical group 0.000 abstract 2
- 125000001118 alkylidene group Chemical group 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 description 25
- WWVKQTNONPWVEL-UHFFFAOYSA-N caffeic acid phenethyl ester Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCC1=CC=CC=C1 WWVKQTNONPWVEL-UHFFFAOYSA-N 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 20
- 230000015572 biosynthetic process Effects 0.000 description 18
- 210000003668 pericyte Anatomy 0.000 description 9
- 230000002093 peripheral effect Effects 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 210000003556 vascular endothelial cell Anatomy 0.000 description 8
- 230000012010 growth Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 238000011729 BALB/c nude mouse Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 210000003725 endotheliocyte Anatomy 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 238000012827 research and development Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 230000001732 thrombotic effect Effects 0.000 description 3
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 210000004504 adult stem cell Anatomy 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 229940074360 caffeic acid Drugs 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N caffeic acid Natural products OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 235000004883 caffeic acid Nutrition 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000012757 fluorescence staining Methods 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000000251 trophoblastic cell Anatomy 0.000 description 2
- -1 3,4-diacetyl phenyl Chemical group 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000002508 compound effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 230000008442 fetal wound healing Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011100721406A CN102198125B (zh) | 2010-12-10 | 2011-03-24 | 咖啡酸苯乙酯类衍生物在制备抗肿瘤血管形成的药物中的用途 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010582759 | 2010-12-10 | ||
CN201010582759.7 | 2010-12-10 | ||
CN2011100721406A CN102198125B (zh) | 2010-12-10 | 2011-03-24 | 咖啡酸苯乙酯类衍生物在制备抗肿瘤血管形成的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102198125A CN102198125A (zh) | 2011-09-28 |
CN102198125B true CN102198125B (zh) | 2013-02-20 |
Family
ID=44659283
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2011100721406A Active CN102198125B (zh) | 2010-12-10 | 2011-03-24 | 咖啡酸苯乙酯类衍生物在制备抗肿瘤血管形成的药物中的用途 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9532967B2 (zh) |
EP (1) | EP2687211A4 (zh) |
CN (1) | CN102198125B (zh) |
WO (1) | WO2012075957A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102198125B (zh) * | 2010-12-10 | 2013-02-20 | 南京埃匹卡生物科技有限公司 | 咖啡酸苯乙酯类衍生物在制备抗肿瘤血管形成的药物中的用途 |
CN104016862A (zh) * | 2013-02-28 | 2014-09-03 | 北京大学 | 咖啡酸苯乙酯酚羟基保护衍生物的制备及其作为神经保护剂和抗肿瘤药物的应用 |
EP3068880A4 (en) * | 2013-11-11 | 2017-06-14 | University Hospitals Cleveland Medical Center | Targeted treatment of anerobic cancer |
WO2017123935A1 (en) * | 2016-01-13 | 2017-07-20 | Cardelli James Allen | Methods for treating c-met-dependent cancers |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1233171A (zh) * | 1996-09-05 | 1999-10-27 | 研究发展基金会 | 用咖啡酸苯乙酯(CAPE)、CAPE的衍生物、辣椒素(8-甲基-N-香兰基-6-壬烯酰胺)和树脂毒素来抑制核转录因子NF-κB |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100968367B1 (ko) * | 2006-10-02 | 2010-07-06 | 재단법인서울대학교산학협력재단 | 카페인산 유도체 및 이를 유효성분으로 포함하는 조성물 |
WO2008083389A1 (en) * | 2006-12-29 | 2008-07-10 | Moleculin, L.L.C. | Methods of treating skin disorders with caffeic acid analogs |
CN102198125B (zh) * | 2010-12-10 | 2013-02-20 | 南京埃匹卡生物科技有限公司 | 咖啡酸苯乙酯类衍生物在制备抗肿瘤血管形成的药物中的用途 |
-
2011
- 2011-03-24 CN CN2011100721406A patent/CN102198125B/zh active Active
- 2011-12-08 WO PCT/CN2011/083718 patent/WO2012075957A1/zh active Application Filing
- 2011-12-08 EP EP11847825.4A patent/EP2687211A4/en not_active Withdrawn
- 2011-12-08 US US13/993,074 patent/US9532967B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1233171A (zh) * | 1996-09-05 | 1999-10-27 | 研究发展基金会 | 用咖啡酸苯乙酯(CAPE)、CAPE的衍生物、辣椒素(8-甲基-N-香兰基-6-壬烯酰胺)和树脂毒素来抑制核转录因子NF-κB |
Non-Patent Citations (3)
Title |
---|
Li Shu-chun et al.Anticancer Activities of Substituted Cinnamic Acid Phenethyl Esters on Human Cancer Cell Lines.《Journal of Chinese Pharmaceutical Sciences》.2003,第 12 卷(第4期),page 184-187. * |
陈鲤翔等.咖啡酸苯乙酯抗血管生成作用机制研究.《科技创新导报》.2007,(第31期),第117页. * |
黄文诚.咖啡酸苯乙酯及其类似物对癌转移的抑制作用.《中国蜂业》.2006,第57卷(第1期),第45页. * |
Also Published As
Publication number | Publication date |
---|---|
US20130303611A1 (en) | 2013-11-14 |
US9532967B2 (en) | 2017-01-03 |
CN102198125A (zh) | 2011-09-28 |
WO2012075957A1 (zh) | 2012-06-14 |
EP2687211A1 (en) | 2014-01-22 |
EP2687211A4 (en) | 2014-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102198125B (zh) | 咖啡酸苯乙酯类衍生物在制备抗肿瘤血管形成的药物中的用途 | |
CN111973748B (zh) | Enpp1抑制剂与抗癌药物联合用药在制备抗肿瘤药物中的应用 | |
CN1157716A (zh) | 转移抑制剂 | |
CN101647796A (zh) | 蛇床子素在制备抑制血管新生药物中的应用 | |
CN106232115A (zh) | 用于治疗抗性的癌症的预防或治疗性组合物 | |
US7468355B2 (en) | Methods for inhibiting cancer and scar formation | |
CN103143013B (zh) | 一种含有氨基多羧酸修饰四苯基卟啉化合物的光敏药物制剂及用途 | |
CN106974908A (zh) | 含有hdac抑制剂和ire1抑制剂的药物组合物及用途 | |
CN102058570A (zh) | 鼠尾草酸在制备抑制血管生成药物中的应用 | |
TW201132342A (en) | Antrocin containing pharmaceutical compositions for inhibiting cancer cells | |
CN104666320A (zh) | 曲札茋苷在制备治疗癌症药物中的应用 | |
CN102058579B (zh) | 去氢木香内酯在制备抑制血管生成药物中的应用 | |
CN100396286C (zh) | 高三尖杉酯碱和三尖杉酯碱在制备抑制血管生成药物中的应用 | |
CN101830819B (zh) | 苯丁酰基姜黄素衍生物及其在制备抗肿瘤药物中的应用 | |
CN109771428A (zh) | 雷公藤红素联合erastin在治疗非小细胞肺癌的药物中的应用 | |
CN106138067A (zh) | 蟾蜍二烯内酯类化合物在制备抗胃癌药物中的应用 | |
US10058611B2 (en) | Use of α-(8-quinolinyloxy) mono-substituted phthalocyanine zinc for treatment of psoriasis | |
CN114617876B (zh) | 一种抗肿瘤联合用药物 | |
RU2682039C1 (ru) | Пептид, обладающий противоопухолевой и антиметастатической активностью, и готовая лекарственная форма на его основе | |
CN102151243B (zh) | 一种紫杉醇注射液及其制备方法 | |
CN107412736A (zh) | 一种抗肿瘤联合用药物及其在制备抗癌药物中的用途 | |
CN100577180C (zh) | 藤黄酸在制备抑制血管生成药物中的应用 | |
CN101116664B (zh) | 化合物1-(4-氯苯胺基)-4-(4-甲基吡啶基)-2,3-二氮杂萘的应用 | |
CN101511355A (zh) | (2z)-2-(3,4-二羟基亚苄基)-1-苯并呋喃-3(2h)-酮在制备抗癌药物中的应用 | |
CN107224580A (zh) | 类α-氨基酸三氟化硼化物在硼中子俘获治疗中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: DU YANSHENG PENG JIRUN MA ZHIZHONG Effective date: 20121206 Owner name: NANJING AIPIKA BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LIU JUNYI Effective date: 20121206 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100191 HAIDIAN, BEIJING TO: 210009 NANJING, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20121206 Address after: 01, building 5, Metro 69, 210009 Olympic Sports Avenue, Jianye District, Jiangsu, Nanjing Applicant after: NANJING AIPIKA BIOLOGICAL SCIENCE & TECHNOLOGY CO., LTD. Address before: 100191 School of pharmacy, Peking University Health Science Center, Xueyuan Road 38, Beijiao, Beijing, Haidian District Applicant before: Liu Junyi Applicant before: Du Yansheng Applicant before: Peng Jirun Applicant before: Ma Zhizhong |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: MAO TENGSHU Free format text: FORMER OWNER: NANJING AIPIKA BIOTECHNOLOGY CO., LTD. Effective date: 20140113 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 100096 HAIDIAN, BEIJING |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140113 Address after: 100096 Beijing Haidian District City Garden 68 Building No. 305, producing up new Patentee after: Mao Tengshu Address before: 01, building 5, Metro 69, 210009 Olympic Sports Avenue, Jianye District, Jiangsu, Nanjing Patentee before: NANJING AIPIKA BIOLOGICAL SCIENCE & TECHNOLOGY CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160725 Address after: 100102 Beijing city Chaoyang District Dongyuan Wangjing No. 523 building 13 layer 11610 Patentee after: Beijing pulse Medical Technology Co., Ltd. Address before: 100096 Beijing Haidian District City Garden 68 Building No. 305, producing up new Patentee before: Mao Tengshu |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180327 Address after: 100096 Beijing Haidian District City Garden 68 Building No. 305, producing up new Patentee after: Mao Tengshu Address before: 100102 Beijing city Chaoyang District Dongyuan Wangjing No. 523 building 13 layer 11610 Patentee before: Beijing pulse Medical Technology Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180608 Address after: 100102 13 floor 11610, Wangjing East Garden 523, Chaoyang District, Beijing. Patentee after: Beijing pulse Medical Technology Co., Ltd. Address before: 100096 305, 68 / F, new West Garden, Haidian District, Beijing. Patentee before: Mao Tengshu |